Pfizer’s Hympavzi receives European approval to treat adults and adolescents with haemophilia A or B with inhibitors: New York Thursday, May 14, 2026, 09:00 Hrs [IST] Pfizer Inc ...
First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline –– Announced FDA Approval of VEPPANU™ ...
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of ...
HYMPAVZI offers a combination of superior bleed protection compared to on-demand (OD) treatment that is well-tolerated with a straightforward, once-weekly subcutaneous injection administration that ...
Thank you, and welcome to the Curis First Quarter 2026 Business Update Call. Before we begin, I'd like to encourag ...
A recent executive order issued by President Trump aims to fast-track research for psychedelics, including ibogaine. What is it?
Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO & DirectorP.
Cap Biopharma Stocks that Could See Big Growth in 2023 Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA ...
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the ...
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results